ePlus vs Td Synnex
PLUS and SNX side by side, both in professional and commercial equipment and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLUS and SNX compare
Td Synnex is the larger company, worth 7.8 times as much as ePlus ($18.9B against $2.4B).
On earnings, Td Synnex is cheaper: it trades at 14.4× trailing earnings, against 19.5× for ePlus.
Td Synnex grew revenue faster over the last twelve months (24.1% versus 16.5% for ePlus).
ePlus keeps more of each dollar of sales as profit, with a net margin of 5.1% compared with 1.8% at Td Synnex.
Both pay dividends: ePlus yields 1.1% and Td Synnex 0.81%.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLUS | SNX |
|---|---|---|
| Size and price | ||
| Market cap | $2.4B | $18.9B |
| Share price | $92.91 | $236.62 |
| Change, 1 year | 28.3% | 52.0% |
| Change, 5 years | 51.8% | 107% |
| Beta (5Y) | 0.98 | 1.05 |
| Employees | 2,148 | 270K |
| StockData Score | ||
| Total score | 15 | 15 |
| Valuation score | 2 | 4 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 4 | 4 |
| Health score | 6 (better) | 2 |
| Dividend score | 2 | 2 |
| Valuation | ||
| P/E | 19.5× | 14.4× (better) |
| P/S | 1.0× | 0.3× (better) |
| P/B | 2.3× | 2.0× (better) |
| EV/EBITDA | 10.1× | 9.6× (better) |
| PEG | 4.96 | 1.05 (better) |
| FCF yield | – | −4.3% |
| Fair value | $84.59 | $249.06 |
| Margin of safety | −9.8% | 5.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.5% | 24.1% (better) |
| Revenue growth, 5Y average | 9.3% | 25.6% (better) |
| Net income growth (TTM) | 4.5% | 71.3% (better) |
| EPS growth (TTM) | 5.5% | 78.0% (better) |
| EPS growth, 5Y average | 12.7% (better) | −0.51% |
| Profitability | ||
| Gross margin | 25.2% (better) | 6.9% |
| Operating margin | 6.9% (better) | 2.7% |
| Net margin | 5.1% (better) | 1.8% |
| FCF margin | – | −1.1% |
| Return on equity | 12.0% | 14.9% (better) |
| Return on invested capital | 20.7% (better) | 12.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.59 (better) |
| Net debt / EBITDA | – | 1.93 |
| Interest coverage | – | 6.4× |
| Current ratio | 2.13 (better) | 1.19 |
| Altman Z-score | 4.69 (better) | 2.62 |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.1% (better) | 0.81% |
| Payout ratio | 21.3% | 11.4% |
| Years of dividend growth | 0 | 5 (better) |
| Dividend growth, 5Y average | – | 34.5% |
| Buyback yield | 2.0% | 2.5% (better) |
| Shareholder yield | 3.1% | 3.3% (better) |
| Ownership | ||
| Held by institutions | 96.6% | 91.8% |
| Held by insiders | 2.1% | 0.68% |
| Insider net buying, 12 months | −$1.6M (better) | −$39.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 5.4% | 2.3% |
Go deeper
- PLUS stock overview
- PLUS income statement
- PLUS valuation and score
- SNX stock overview
- SNX income statement
- SNX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.